Register to attend a free NIH webinar. Attendees will learn about a new family of Proteolysis Targeting Chimeras (PROTACS) that selectively target Proviral Integration for the Moloney murine leukemia virus (PIM) kinases which have roles in cancer development and mediating resistance to radio and chemotherapy; and is overexpressed in multiple cancers. Several small molecule PIM kinase inhibitors have had minimal effect in suppressing cancer phenotypes due to the PIM kinase inhibitors promoting intrinsic resistance. By contrast, these PIM targeted PROTACs suppress PIM kinase activity by completely degrading the PIM kinase proteins – intrinsic resistance is therefore avoided.